{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:28:54Z","timestamp":1767968934985,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13104-019-4113-7","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T14:05:15Z","timestamp":1549893915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case\u2013control study"],"prefix":"10.1186","volume":"12","author":[{"name":"the MoMar study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Gilbert","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Brik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swaantje","family":"Casjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Burek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Pesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Taeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Johnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"issue":"4","key":"4113_CR1","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491\u20136.","journal-title":"Ann Cardiothorac Surg"},{"issue":"3","key":"4113_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","volume":"92","author":"JT Hodgson","year":"2005","unstructured":"Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92(3):587\u201393.","journal-title":"Br J Cancer"},{"issue":"10026","key":"4113_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet"},{"issue":"2","key":"4113_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/imt-2017-0144","volume":"10","author":"S Brosseau","year":"2018","unstructured":"Brosseau S, Dhalluin X, Zalcman G, Scherpereel A. Immunotherapy in relapsed mesothelioma. Immunotherapy. 2018;10(2):77\u201380.","journal-title":"Immunotherapy"},{"key":"4113_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.12659\/AJCR.909584","volume":"19","author":"RG Jones","year":"2018","unstructured":"Jones RG, Karthik F, Dugar A, Kanagarajan K, Desai K, Bhandari M. Nivolumab immunotherapy in malignant mesothelioma: a case report highlighting a new opportunity for exceptional outcomes. Am J Case Rep. 2018;19:783\u20139.","journal-title":"Am J Case Rep"},{"issue":"Suppl 9","key":"4113_CR6","doi-asserted-by":"publisher","first-page":"S1003","DOI":"10.21037\/jtd.2018.04.31","volume":"10","author":"T Ahmadzada","year":"2018","unstructured":"Ahmadzada T, Reid G, Kao S. Biomarkers in malignant pleural mesothelioma: current status and future directions. Journal of thoracic disease. 2018;10(Suppl 9):S1003\u20137.","journal-title":"Journal of thoracic disease"},{"key":"4113_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-018-0492-1","volume":"10","author":"H Wang","year":"2018","unstructured":"Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018;10:59.","journal-title":"Clin Epigenetics"},{"issue":"7","key":"4113_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","volume":"16","author":"XJ Lin","year":"2015","unstructured":"Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804\u201315.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4113_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.canlet.2016.01.028","volume":"373","author":"L Li","year":"2016","unstructured":"Li L, Chen J, Chen X, Tang J, Guo H, Wang X, Qian J, Luo G, He F, Lu X, et al. Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma. Cancer Lett. 2016;373(2):234\u201340.","journal-title":"Cancer Lett"},{"key":"4113_CR10","doi-asserted-by":"publisher","first-page":"9645940","DOI":"10.1155\/2017\/9645940","volume":"2017","author":"P Mozzoni","year":"2017","unstructured":"Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, et al. MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study. Dis Markers. 2017;2017:9645940.","journal-title":"Dis Markers"},{"issue":"5","key":"4113_CR11","doi-asserted-by":"publisher","first-page":"e0176680","DOI":"10.1371\/journal.pone.0176680","volume":"12","author":"T Cavalleri","year":"2017","unstructured":"Cavalleri T, Angelici L, Favero C, Dioni L, Mensi C, Bareggi C, Palleschi A, Rimessi A, Consonni D, Bordini L, et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS ONE. 2017;12(5):e0176680.","journal-title":"PLoS ONE"},{"issue":"1","key":"4113_CR12","doi-asserted-by":"publisher","first-page":"e30221","DOI":"10.1371\/journal.pone.0030221","volume":"7","author":"DG Weber","year":"2012","unstructured":"Weber DG, Johnen G, Bryk O, Jockel KH, Bruning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma\u2014a pilot study. PLoS ONE. 2012;7(1):e30221.","journal-title":"PLoS ONE"},{"issue":"4","key":"4113_CR13","doi-asserted-by":"publisher","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","volume":"6","author":"L Santarelli","year":"2011","unstructured":"Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS ONE. 2011;6(4):e18232.","journal-title":"PLoS ONE"},{"issue":"7","key":"4113_CR14","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","volume":"7","author":"MB Kirschner","year":"2012","unstructured":"Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7):1184\u201391.","journal-title":"J Thorac Oncol"},{"key":"4113_CR15","doi-asserted-by":"publisher","first-page":"9280170","DOI":"10.1155\/2017\/9280170","volume":"2017","author":"DG Weber","year":"2017","unstructured":"Weber DG, Gawrych K, Casjens S, Brik A, Lehnert M, Taeger D, Pesch B, Kollmeier J, Bauer TT, Johnen G, et al. Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma. Dis Markers. 2017;2017:9280170.","journal-title":"Dis Markers"},{"issue":"5","key":"4113_CR16","first-page":"874","volume":"1844","author":"B Pesch","year":"2014","unstructured":"Pesch B, Bruning T, Johnen G, Casjens S, Bonberg N, Taeger D, Muller A, Weber DG, Behrens T. Biomarker research with prospective study designs for the early detection of cancer. Biochem Biophys Acta. 2014;1844(5):874\u201383.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"4113_CR17","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","volume":"8","author":"G Johnen","year":"2018","unstructured":"Johnen G, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, Lehnert M, Casjens S, Hagemeyer O, Taeger D, et al. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin\u2014a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Sci Rep. 2018;8(1):14321.","journal-title":"Sci Rep"},{"issue":"4","key":"4113_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"7043","key":"4113_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nature03702","volume":"435","author":"J Lu","year":"2005","unstructured":"Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834\u20138.","journal-title":"Nature"},{"issue":"1","key":"4113_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1373\/clinchem.2014.221341","volume":"61","author":"KW Witwer","year":"2015","unstructured":"Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem. 2015;61(1):56\u201363.","journal-title":"Clin Chem"},{"issue":"3","key":"4113_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","volume":"11","author":"H Schwarzenbach","year":"2014","unstructured":"Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145\u201356.","journal-title":"Nat Rev Clin Oncol"},{"key":"4113_CR22","doi-asserted-by":"publisher","first-page":"681416","DOI":"10.1155\/2015\/681416","volume":"2015","author":"O Blyuss","year":"2015","unstructured":"Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF. Serial patterns of ovarian cancer biomarkers in a prediagnosis longitudinal dataset. Biomed Res Int. 2015;2015:681416.","journal-title":"Biomed Res Int"},{"issue":"1","key":"4113_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","volume":"17","author":"G Johnen","year":"2017","unstructured":"Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17(1):386.","journal-title":"BMC Cancer"},{"issue":"9","key":"4113_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.7150\/ijms.23939","volume":"15","author":"G Aguilar-Madrid","year":"2018","unstructured":"Aguilar-Madrid G, Pesch B, Calderon-Aranda ES, Burek K, Jimenez-Ramirez C, Juarez-Perez CA, Ochoa-Vazquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, et al. Biomarkers for predicting malignant pleural mesothelioma in a mexican population. Int J Med Sci. 2018;15(9):883\u201391.","journal-title":"Int J Med Sci"},{"issue":"12","key":"4113_CR25","doi-asserted-by":"publisher","first-page":"e114483","DOI":"10.1371\/journal.pone.0114483","volume":"9","author":"DG Weber","year":"2014","unstructured":"Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, Kollmeier J, Bauer TT, Bruning T. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS ONE. 2014;9(12):e114483.","journal-title":"PLoS ONE"},{"key":"4113_CR26","first-page":"56","volume":"4","author":"MB Kirschner","year":"2013","unstructured":"Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genetics. 2013;4:56.","journal-title":"Front Genetics"},{"issue":"3","key":"4113_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","volume":"5","author":"CC Pritchard","year":"2012","unstructured":"Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res. 2012;5(3):492\u20137.","journal-title":"Cancer Prev Res"},{"issue":"1","key":"4113_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/ol.2016.5452","volume":"13","author":"S Pizzamiglio","year":"2017","unstructured":"Pizzamiglio S, Zanutto S, Ciniselli CM, Belfiore A, Bottelli S, Gariboldi M, Verderio P. A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncol Lett. 2017;13(1):315\u201320.","journal-title":"Oncol Lett"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4113-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:12:21Z","timestamp":1581379941000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4113-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4113"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4113-7","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"77"}}